enVVeno Medical (NVNO) Net Income towards Common Stockholders (2017 - 2026)

enVVeno Medical's Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$3.8 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders rose 44.75% year-over-year to -$3.8 million; the TTM figure through Jun 2026 stood at -$16.8 million (up 31.27% YoY), while the FY2025 annual figure was -$20.9 million, up 12.13% from the prior year.
• Net Income towards Common Stockholders for Q2 2026 stood at -$3.8 million, up from -$4.0 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$3.8 million in Q2 2026, with the low at -$7.7 million in Q4 2023.
• The 5-year median for Net Income towards Common Stockholders is -$5.8 million (2024), against an average of -$5.8 million.
• The sharpest annual moves came in 2022 and 2026: Net Income towards Common Stockholders plunged 155.35% in 2022, then surged 44.75% in 2026.
• enVVeno Medical's Net Income towards Common Stockholders stood at -$6.7 million in 2022, then decreased by 14.24% to -$7.7 million in 2023, then increased by 10.8% to -$6.8 million in 2024, then surged by 37.02% to -$4.3 million in 2025, then climbed by 12.11% to -$3.8 million in 2026.
• Business Quant data shows NVNO's Net Income towards Common Stockholders at -$3.8 million in Q2 2026, -$4.0 million in Q1 2026, and -$4.3 million in Q4 2025.